- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medtronic Receives CE Mark for MiniMed 670G Hybrid Closed Loop System
Medtronic (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system – the first and only system to automate and personalize the delivery of basal insulin 24 hours a day. The system is CE Mark approved for the treatment of people with …
Medtronic (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the MiniMed(TM) 670G hybrid closed loop system – the first and only system to automate and personalize the delivery of basal insulin 24 hours a day. The system is CE Mark approved for the treatment of people with type 1 diabetes 7 years of age and older with ongoing studies to expand the indication to additional patient populations.
As quoted in the press release:
“We’re proud to introduce our most advanced SmartGuard Auto Mode algorithm outside of the United States, which not only helps to prevent lows but works to drive Time in Range – a most important measure of the effect of diabetes management on a patient’s glucose levels – by decreasing time in hyperglycemia,” said Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic. “The MiniMed 670G system advances our ability to automatically suspend and resume insulin delivery to the next level by automating self-adjusting basal insulin delivery every 5 minutes based on sensor glucose values – providing the most advanced algorithm available to deliver leading clinical outcomes.”
The company’s most advanced SmartGuard(TM) technology and most accurate2 continuous glucose monitor (CGM) – the Guardian(TM) Sensor 3 – work together to self-adjust basal insulin delivery to offer protection against both highs and lows, helping to improve Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL or 3.9-10 mmol/L)3,4. SmartGuard technology is the only smart algorithm that can adapt to fluctuating glucose levels and automatically self-adjust background insulin delivery to stabilize them. This advanced algorithm mimics some of the functions of a healthy pancreas and is the only technology in the world that proactively drives an increase in Time in Range – addressing both highs and lows. The system also exclusively features the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system from Ascensia Diabetes Care.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.